## CERTIFICATE OF EFS FILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office, Commissioner for Patents, via the EFS pursuant to 37 CFR §1.8 on the below date:

Date

Name: Stoven Oberholtzer

Signature: /Steven Oberholtzer/ Reg No. 30 670

BRINKS HOFER GILSON &LIONE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:			
MICHAEL J. BORRELI			
Serial-No. 10/764,316		į.	Examiner: Chong, Kimberly
Filin	ng Date: January 23, 2004  METHODS AND COMPOSITIONS FOR ACTIVATED GENE THERAPY USING CYTOLETHAL DISTENDING TOXIN	i i	Group Art Unit No. 1635 Confirmation No.
Mail	TRANSIN	IITTAL	8323 Docket No. 10546/109
Comi P. O.	missioner for Patents Box 1450 andria, VA 22313-1450		
Sir:			
Attached is/are:  Transmittal; Petition for Revival of Application Unintentionally Abandoned (2 pgs); Corrected Amendment After Final (4 pgs).  Fee calculation:  No additional fee is required.  Small Entity.  An extension fee in an amount of \$ for amonth extension of time under 37 CFR § 1.136(a).  A petition or processing fee in an amount of \$770 under 37 CFR § 1.17(m).  Fee payment:  Please charge Deposit Account No. 23-1925 in the amount of \$770 for petition fee.  Payment by credit card in the amount of \$ (Form PTO-2038 is attached).  The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit Account No. 23-1925.  Respectfully submitted,			
January 18, 2008 Date		/Steven Oberholtzer/ Steven Oberholtzer (Reg. No. 30,670)	
		5.5.5 5.60monzor (1.6g. 140. 50,070)	